SvetinormСветинорм
An animal liver peptide mixture investigated in a Russian institute report on symptoms and liver enzyme levels.
What the studies found
Comparison in people · 2013
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
Study of multiple preparations
- Total cholesterol
- 7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4.Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable.
- VLDL cholesterol
- 1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07.Both adjunctive groups are marked significant versus standard care.
- Reported fatigue
- 64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%.Only the four-product group is marked significant versus standard care in the fatigue row.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Study notes · methods, sources and limitations
Participants or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
Design Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.
Important limitations
- The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten. Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods. The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified. Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
- The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides. · Conference report · company reproduction
Comparison in people · 2006
Svetinorm: clinical report on a tissue-derived preparation
- Bilirubin
- 20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L.
- ALT in the report’s stated units
- 43.5 ± 3.5 with Svetinorm and 46.1 ± 3.8 with conventional care. Shared baseline 52.5 ± 4.1. Both arms were marked significant versus baseline.
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
Design 47 adults received Svetinorm plus usual care and 38 controls received usual care. The group methods describe two capsules twice daily before meals for 15–20 days.
Important limitations
- A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
- The table gives a shared baseline and reports significance against baseline.
Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction
About Svetinorm
Identity / background source ↗
Research background
Svetinorm is a liver-derived peptide preparation. A Medical Center report compared symptoms and liver blood tests during adjunctive care.
- Compound class
- Tissue-derived peptide preparation
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
Study methods
Small comparative institute report; allocation, blinding and outcome interpretation require caution
Independent replication
Independent replication not established in this collection
Source access
Report reproduction linked; source language and review scope shown per record
Safety evidence
Short-term reports do not establish long-term safety or equivalence to current products
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2013
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Study notes and original source
Ventfort, Cerluten, Svetinorm and Endoluten in cerebral atherosclerosis
Oral vascular, brain, liver and pineal polypeptide preparations added to standard therapy · Conference report · company reproduction
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 20th IAGG World Congress, Seoul, 2013. Conference material reproduced by Peptides.
The conference table reports total cholesterol of 7.6 mmol/L with standard care, 6.3 with Ventfort and Cerluten, and 5.8 with the four-product combination.
Results and tables
Reported findings and study design
Moscow, December 2011 to June 2012. Standard treatment alone (514), with Ventfort and Cerluten (319), or with those two plus Svetinorm and Endoluten (416). The Russian methods list two oral capsules each per day for three months for Ventfort, Cerluten and Svetinorm when assigned. Endoluten was one morning capsule daily for two months. Active mass per capsule is unspecified.
Population or model 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Total cholesterol | 7.6 ± 0.3 mmol/L standard care, 6.3 ± 0.5 with two products, 5.8 ± 0.6 with four products. Shared baseline 8.7 ± 0.4. | Both adjunctive groups are marked significant versus standard care. Exact p values are unavailable. |
| VLDL cholesterol | 1.22 ± 0.06, 0.92 ± 0.07 and 0.87 ± 0.05 mmol/L, respectively. Shared baseline 1.42 ± 0.07. | Both adjunctive groups are marked significant versus standard care. |
| Reported fatigue | 64.0%, 32.3% and 12.9%, respectively. Shared baseline 75.6%. | Only the four-product group is marked significant versus standard care in the fatigue row. |
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing the preparations. The comparison was conducted at the Moscow branch of the Centre for Revitalization and Health. Symptom assessment and statistical methods are incompletely reported. The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 1,249 adults aged 55–65: 514 standard care, 319 standard care with Ventfort and Cerluten, 416 standard care with all four preparations.
- Source reviewed
- Authors’ conference material, Russian reproduction, PDF pages 8–10, methods and Tables 1–2. English and Russian editions describe the same comparison.
Study limitations
- The authors excluded statin users and people with prior stroke. The comparison provides no individual estimates for Svetinorm or Endoluten.
- Both editions name Svetinorm in the four-product group and outcome tables. The English dosing list instead says Suprefort. The schedule below follows the Russian methods.
- The table gives one shared pretreatment column. Methods of allocation and masking, timing of the reported tables and adverse-event ascertainment are unspecified.
- Table 1 repeats the triglyceride heading with values of unclear identity. The cholesterol, VLDL and first triglyceride rows are legible.
- The Seoul report describes two comparisons from the same Moscow center. Recruitment dates overlap and participant-level linkage is unavailable.
Reviewed 2026-11-16.
Comparison in people · 2006
Svetinorm: clinical report on a tissue-derived preparation
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
Bilirubin · 20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L.
Study notes and original source
Svetinorm: clinical report on a tissue-derived preparation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date
Bilirubin was 20.1 µmol/L after adjunctive Svetinorm and 23.6 µmol/L after conventional care. The table marks a change from the shared baseline of 27.1 µmol/L.
Results and tables
Reported findings and study design
47 adults received Svetinorm plus usual care and 38 controls received usual care. The group methods describe two capsules twice daily before meals for 15–20 days.
Population or model 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Bilirubin | 20.1 ± 0.8 µmol/L with Svetinorm and 23.6 ± 1.4 µmol/L with conventional care. Shared baseline 27.1 ± 1.2 µmol/L. | |
| ALT in the report’s stated units | 43.5 ± 3.5 with Svetinorm and 46.1 ± 3.8 with conventional care. Shared baseline 52.5 ± 4.1. Both arms were marked significant versus baseline. |
The table gives a shared baseline and reports significance against baseline.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 85 patients: 47 adjunctive Svetinorm; 38 controls. Chronic hepatitis or care following radiation/chemotherapy.
- Source reviewed
- Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
- A within-group change is not proof of superiority over controls. Mixed diagnoses, co-treatments and incomplete allocation reporting limit interpretation.
- Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
- Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
Reviewed 2026-11-16.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗